Market Cap $110.9M
!


Corporate Spotlight
Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.
View the full Corporate Spotlight
PAR - close to a cure for osteoarthritis?
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
PAR | Where are we on a deal? | 06/06/25 | 1.3K | 432K | |||
|
|||||||
PAR | outcomes of the meeting on 29 may | 06/06/25 | 103 | 32K | |||
|
|||||||
PAR | Ann: Phase 3 Knee OA Trial Begins, Site Live, Patient Consented | 06/06/25 | 32 | 10K | |||
|
|||||||
PAR | Paradigm activates first Aus site for osteoarthritis drug trials | 03/06/25 | 1 | 603 | |||
|
|||||||
PAR | OARSI 2025 | 02/06/25 | 53 | 20K | |||
|
|||||||
PAR | PAR 7 & Psoriasis | 02/06/25 | 30 | 13K | |||
|
|||||||
PAR | Ann: Results of Meeting | 30/05/25 | 1 | 851 | |||
|
|||||||
PAR | Competition??? | 29/05/25 | 129 | 53K | |||
|
See All Discussions
Timeline
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
View More |